JNJ vs SNDX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and SNDX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and SNDX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Syndax Pharmaceuticals (Nasdaq: SNDX) sells two approved medicines and funds a pipeline behind them. Revuforj (revumenib) is an oral menin inhibitor, approved by the FDA on November 15, 2024 for relapsed or refractory acute leukemia carrying a KMT2A translocation in patients one year and older, then expanded on October 24, 2025 into relapsed or refractory AML with a susceptible NPM1 mutation. Syndax owns it outright in the US, licensed originally from Vitae Pharmaceuticals, now an AbbVie subsidiary, and books its sales as product revenue. Niktimvo (axatilimab-csfr) is a first-in-class antibody against the CSF-1 receptor, approved in August 2024 for chronic graft-versus-host disease after at least two prior lines of systemic therapy in patients weighing 40kg or more. It was in-licensed from UCB Biopharma in 2016 and then partnered with Incyte in September 2021 under a worldwide co-development and co-commercialization agreement. Incyte runs the commercial engine and records the sales; Syndax takes half the net commercial profit. In the second quarter of 2026 Revuforj generated $54.7M of net product revenue on roughly 1,500 prescriptions, while Niktimvo generated $60.3M of net sales at Incyte, of which $18.1M reached Syndax. The company employed about 298 people at last count.

Full SNDX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
• SNDX drivers: Revuforj moving from KMT2A into the far larger NPM1 population; Niktimvo, where Syndax sees half the profit and none of the sales line.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For SNDX, revuforj no longer has the menin inhibitor class to itself.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; SNDX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and SNDX guides.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

SNDX. Seven times sales is not a demanding multiple for a biotech growing revenue at triple digits, and the reason it is not higher is visible in the structure rather than the growth rate. Half the franchise arrives as a profit share, the Royalty Pharma instrument skims 13.8% of US Niktimvo sales before anything reaches Syndax, and both drugs are approved only in later-line settings where the patient pool is finite. Twelve covering analysts carried a mean target near $37.55 in August 2026, which is a frontline-expansion number rather than a run-rate one.

Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; SNDX shows revenue (ttm) ~$252.3M for the twelve months to June 30, 2026, against $172.4M in fiscal 2025 and $23.7M in fiscal 2024. The quarterly path was $68.7M in 4Q25, $64.9M in 1Q26 (a sequential dip driven by the January payer and gross-to-net reset, not by demand) and $72.8M in 2Q26, the last of which was up 92% year over year., product mix (the line that misleads screeners) Of 2Q26's $72.8M, $54.7M was Revuforj net product revenue and $18.1M was collaboration revenue representing Syndax's 50% share of Niktimvo net commercial profit. Incyte separately reported $60.3M of Niktimvo net sales in the quarter. Combined branded sales of the two medicines were therefore ~$115.0M in 2Q26 and over $275M across full-year 2025 ($124.8M Revuforj plus $151.6M Niktimvo), well above the reported revenue line., earnings and eps Net loss of $49.4M, or $0.55 per share, in 2Q26 versus $71.8M and $0.83 a year earlier; $92.0M and $1.04 per share for the first half of 2026 versus $156.7M and $1.82. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. Operating loss narrowed to $40.0M in 2Q26 from $69.4M. There is no P/E, and there has never been an annual profit., operating expenses and guidance 2Q26 R&D was $68.0M (from $62.2M), SG&A $41.5M (from $43.8M) and cost of product sales $3.2M, for $112.8M of total opex. First-half opex was $211.8M against $210.9M a year earlier, so spend is roughly flat while revenue grew 138%. Guidance for full-year 2026 is approximately $400M of R&D plus SG&A excluding ~$50M of estimated non-cash stock compensation, down from $438.5M actual in 2025..

JNJ and SNDX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and SNDX exposure against your real portfolio. It is not an investment adviser.